CUTISS Turns to the EIC Accelerator to Automate Lab-Grown Skin
The standard treatment for a deep burn is to shave a thin layer of healthy skin from elsewhere on the patient and move it to the wound, a method that runs out of donor skin in the worst cases and leaves scars that do not stretch as children grow, as the University of Zurich described it in January 2026. CUTISS, a spin-off of that university based in Schlieren near Zurich, grows a replacement instead: a two-layer graft of dermis and epidermis cultivated from the patient's own cells, starting from a biopsy about the size of a postage stamp.
On 16 November 2026 the European Innovation Council announced 35 companies selected from the May and July 2026 cut-offs. CUTISS is on the list with denovoProd, a project for "Fully Automated GMP Manufacturing of denovoSkin(tm) for skin surgery applications", recommended for blended finance from the cut-off of 8 July 2026. Selection is not yet a funding commitment: the EIC expects to finalise the grant agreements within three months, and no denovoProd project appears in CORDIS in searches on 17 November 2026.
Company file
- Legal entity
- CUTISS AG, UID CHE-233.237.662, seat in Schlieren, canton of Zurich
- Registered
- 8 March 2017, as a spin-off of the University of Zurich
- Co-founders
- Daniela Marino (CEO), Ernst Reichmann, Fabienne Hartmann-Fritsch, Martin Meuli and Clemens Schiestl
- Chair
- Achim von Leoprechting, former CEO of Tecan, since June 2026
- Lead product
- denovoSkin, an autologous bio-engineered skin graft, in Phase 3
- Known investors
- Giammaria Giuliani's family office, a US family represented by Shiloh Advisors AG, the Wyss Foundation, Rode Kruis Ziekenhuis
- EIC project
- denovoProd, blended finance, cut-off 8 July 2026, not yet in CORDIS
Skin grown from a biopsy
The graft is built from two cell types taken from the same small biopsy: fibroblasts for the lower, dermal layer and keratinocytes for the surface. The CORDIS summary of an earlier EU project describes denovoSkin as a patented, personalised, autologous graft classified as an Advanced Therapy Medicinal Product, with Orphan Drug Designation for burns from Swissmedic, the European Medicines Agency and the US Food and Drug Administration. Because the cells are the patient's own, the UZH article notes there is no risk of rejection, and it reports that the company can now grow several grafts of 50 square centimetres each within four weeks.
denovoProd targets how the graft is made. The company's website describes a patented, fully closed, end-to-end automation platform for decentralised production. On 13 May 2026 CUTISS announced US Patent No. 12,599,401 B2, granted on 14 April 2026, covering automated methods that split a biopsy into dermis and epidermis, expand the two cell types and form the graft under machine control.
Who builds the machines
In April 2025 CUTISS and the Swiss laboratory automation company Tecan announced a partnership to move the platform "from engineering development to industrial-grade production", as Startups Magazine reported on 14 April 2025. Tecan's chief executive at the time, Achim von Leoprechting, was quoted in that announcement. Fourteen months later CUTISS elected him chair of its board, succeeding co-founder Martin Meuli, who stays a board member. The commercial register entry of 14 July 2026 records the change.
The EIC has funded this before
denovoProd is not CUTISS's first EU-funded attempt at automation. CORDIS lists three closed Horizon 2020 grants, each with CUTISS as sole coordinator. A Phase 1 SME Instrument grant of €50,000 ran from January to April 2018 to plan the clinical validation and industrialisation of denovoSkin. The Phase 2 grant under the EIC SME Instrument, the predecessor of the Accelerator, then ran from 1 October 2018 to 31 December 2020 with an EU contribution of €2,499,866.25 out of €3,571,237.50 in total costs; its objective was to automate production and support market entry. A third grant, SkinFactory 2.0, had an EU contribution of €183,125 from November 2019 to November 2020 for an innovation associate to help develop the automated manufacturing system.
The EU money so far
Three closed Horizon 2020 grants, all for denovoSkin
CORDIS records three grants to CUTISS as sole coordinator between 2018 and 2020, the largest an SME Instrument Phase 2 grant for automating production and preparing market entry. The 2026 denovoProd award has no published amount or CORDIS record yet.
CORDIS, projects 830454, 861242 and 808131. EU contribution in € thousands.
Six years after the Phase 2 grant ended, the automated system is still being industrialised rather than in routine use, by the company's own account: the 2025 Tecan announcement describes the move to industrial-grade production as ongoing, and the UZH article of January 2026 calls the Tecan work the last development step before clinical use. The CORDIS results summary of the 2018 Phase 2 project reports only partial success in adapting cell expansion technology, a switch from one integrated device to three modules, and two prototypes, with GMP integration of the modules left for a next phase of about three years.
The record
Nine years from spin-off to a second EIC selection
CUTISS has been in clinical development for its whole life as a company. The market authorisation the company targeted for 2022 has not arrived; the Phase 3 trial's primary completion is estimated for June 2027.
- Mar 2017Company registeredCUTISS AG entered in the Zurich commercial register on 8 March 2017 as a University of Zurich spin-off
- Oct 2018SME Instrument Phase 2denovoSkin project starts under the EIC SME Instrument, running to 31 December 2020€2.5M EU
- Jun 2020Series BRound targeting CHF 20 million closes oversubscribed; the company aims for market authorisation in 2022
- Dec 2021GMP certificationSwissmedic certifies the company's own 150 square metre facility in Schlieren
- Dec 2024Phase 3 startsBurns trial in adolescents and adults starts on 13 December 2024, per its registry entry
- Apr 2025Tecan partnershipTecan is engaged to industrialise the automated manufacturing platform
- Sep 2025Series CCHF 56 million closed, total funding above CHF 125 million, per the companyCHF 56M
- Jul 2026denovoProd applicationProject counted in the EIC Accelerator cut-off of 8 July 2026
- Nov 2026SelectedOne of 35 companies announced by the EIC, recommended for blended financeSelected
- Jun 2027Phase 3 primary completionEstimated date in the ClinicalTrials.gov recordScheduled
Moneyhouse (Zurich commercial register); CORDIS 808131, 830454 and 861242; Startupticker, 29 June 2020; Greater Zurich Area, 9 March 2022; ClinicalTrials.gov NCT06745557; CUTISS news; EIC, 16 November 2026.
What the trials show
The clinical record is more public than the manufacturing one. On 2 December 2025 CUTISS announced a paper in eClinicalMedicine on its Phase 2 trial in adolescent and adult burn patients at four centres in Switzerland, the Netherlands and Italy, reporting higher expansion from a small biopsy and less scarring than split-thickness grafts. On 31 March 2026 it announced a paper in the Journal of Tissue Engineering on 23 patients in reconstructive surgery, which the company says showed significantly better scar quality than standard grafts at 3 months, maintained at 12 months. Both trials compared denovoSkin with the patient's own standard graft on a control area, and the results above are the company's summaries of the papers.
The confirmatory test is the Phase 3 trial in adolescents and adults with severe burns. Its ClinicalTrials.gov record, updated on 10 August 2026, shows CUTISS as sponsor, 19 listed sites in nine countries (Belgium, France, Germany, Italy, the Netherlands, Poland, Portugal, Spain and Switzerland), an estimated 70 patients, and a composite primary endpoint of wound closure plus scar quality at six months. Primary completion is estimated for 30 June 2027 and study completion for 30 June 2029.
The evidence base
The Phase 3 trial is three times the published reconstructive study
The published Phase 2 reconstructive surgery study treated 23 patients. The Phase 3 burns trial plans to enrol 70, an estimate in the registry entry, with each patient's own standard graft as the control.
CUTISS, 31 March 2026, on the Journal of Tissue Engineering paper; ClinicalTrials.gov NCT06745557, updated 10 August 2026.
The sources date the start differently. The registry gives an actual start of 13 December 2024, the month in which the EMA authorised the trial according to Startups Magazine in February 2025; the company's release of September 2025 says the trial started earlier in 2025, and the UZH article says spring 2025. Tech.eu reported in September 2025 that the first dataset was expected by the end of 2026; sources reviewed on 17 November 2026 show no Phase 3 readout.
Use outside the trials
The UZH article says the graft has been used in eight individual compassionate cases over the past decade, and that after the Crans-Montana fire, biopsies from some burn patients were sent to CUTISS at the discretion of their treating physicians. No outcome from those cases had been published in sources reviewed on 17 November 2026.
The money behind it
CUTISS is financed mainly by families and private investors. In June 2020 Startupticker reported a Series B round that targeted CHF 20 million and was oversubscribed, led by Giammaria Giuliani of the Gisev Family Office, with the Wyss Foundation taking part. On 10 September 2025 the company announced a CHF 56 million Series C, saying it brought total funding above CHF 125 million; Tech.eu named the co-leads as Giuliani's family office and a US family represented by Shiloh Advisors AG. The Dutch burn centre Rode Kruis Ziekenhuis in Beverwijk joined as an investor and signed an agreement that, according to the release, could lead to the company's first international commercial production site in the Netherlands, contingent on approval.
The private money
A CHF 56M Series C took company funding past CHF 125M
All three figures are company-announced. The Series B figure is the round's target, which Startupticker reported as oversubscribed without giving the final total. The cumulative figure includes rounds whose individual sizes are reported inconsistently.
Startupticker, 29 June 2020; CUTISS release via BioSpace, 10 September 2025; UZH Innovation Hub, 22 September 2025. Values in CHF millions.
The register shows the capital still moving. Moneyhouse, which reproduces the Swiss Official Gazette of Commerce, lists an ordinary increase of share capital from CHF 457,469.90 to CHF 473,489.10, with statutes amended on 26 March 2026, and a further increase through conditional capital to CHF 487,739.70, published on 11 September 2026. The company is registered as active, with PricewaterhouseCoopers AG as auditor since October 2024. Production for the trials runs in its own facility in the Bio-Technopark Schlieren, which Swissmedic certified for GMP in December 2021, according to the Greater Zurich Area agency's report of 9 March 2022. The EIC announcement says 32 of the 35 selected companies will be assessed by the EIC Fund for equity of up to €10 million each; neither the EIC nor CUTISS had announced an EIC Fund investment in the company by 17 November 2026, and the grant amount for denovoProd is not public.
Why it matters to Europe
Swiss companies feature strongly in this round: the EIC says the 35 selected companies come from 17 EU and associated countries, with the highest numbers from France, Switzerland and Germany. CUTISS's Phase 3 trial runs across eight EU member states and Switzerland, the kind of multi-country study the Commission's life sciences strategy of 2 July 2025 promises to make easier to fund. The company's website pitches automation as a route to decentralised production; denovoProd is meant to show that it works at scale.
What can be checked so far
- EIC selection for denovoProdSelectedListed in the EIC announcement of 16 November 2026, blended finance; no grant agreement in CORDIS yet.
- Fully automated GMP manufacturingToo earlyA granted US patent and a Tecan industrialisation partnership exist; sources reviewed on 17 November 2026 show no published automated GMP production run.
- Clinical efficacy against standard graftsPhase 2 publishedTwo Phase 2 papers, in eClinicalMedicine (2025) and the Journal of Tissue Engineering (2026); Phase 3 still recruiting.
- Market authorisationNot yetNo approval in sources reviewed on 17 November 2026; the CEO told UZH that Phase 3 data are needed first.
What the company said
In June 2020, CUTISS said it aimed to seek market authorisation in Switzerland and the EU in 2022 and to build a prototype machine that produces large quantities of skin from a small sample, per Startupticker.
What the record shows
A Phase 3 trial started in December 2024 with primary completion estimated for June 2027, published Phase 2 data, a GMP-certified facility in Schlieren and a patented automation platform still being industrialised with Tecan.
Verdict
CUTISS brings the EIC more clinical evidence than most early-stage applicants can show: published randomised Phase 2 data, a confirmatory trial in nine countries and more than CHF 125 million of private backing by its own count. The weak point is the one denovoProd targets. The EU funded a project to automate denovoSkin production once already, from 2018 to 2020, and the machines are still on their way to industrial use, while the 2022 approval target set in 2020 has given way to a Phase 3 readout estimated for 2027. A second grant can be judged on whether a closed, automated line makes grafts for patients outside trials.
The reporting is based on publicly available sources, listed below.
Sources
- EIC, The European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026
- CUTISS, company website
- Moneyhouse, CUTISS AG, CHE-233.237.662, with Swiss Official Gazette of Commerce entries
- CORDIS, denovoSkin, SME Instrument Phase 2, grant agreement 830454
- CORDIS, Results in Brief for denovoSkin, grant agreement 830454
- CORDIS, denovoSkin, SME Instrument Phase 1, grant agreement 808131
- CORDIS, SkinFactory 2.0, grant agreement 861242
- ClinicalTrials.gov, NCT06745557, Phase III study of an autologous dermo-epidermal skin substitute in burns
- University of Zurich, New skin for burn victims, 15 January 2026
- CUTISS via BioSpace, CHF 56M Series C and agreement with an EU burn center, 10 September 2025
- Tech.eu, CUTISS secures €57.9M Series C, 10 September 2025
- Startupticker, CUTISS closes Series B funding, 29 June 2020
- Startups Magazine, CUTISS and Tecan advance skin tissue manufacturing automation, 14 April 2025
- Startups Magazine, CUTISS reports positive Phase 2 results, 12 February 2025
- CUTISS, Phase 2 burns readout published in eClinicalMedicine, 2 December 2025
- CUTISS, 1-year Phase II results in reconstructive surgery, 31 March 2026
- Journal of Tissue Engineering, Phase II reconstructive surgery trial of bio-engineered skin grafts
- CUTISS, US patent for automated skin graft production methods, 13 May 2026
- CUTISS, Achim von Leoprechting elected chairman, 23 June 2026
- Greater Zurich Area, CUTISS now producing artificial skin in its own facility, 9 March 2022
- European Commission, life sciences strategy, 2 July 2025
Industry
HealthBiopharmaceuticals
- Focus
- Cell therapies
- Technologies
- Tissue engineering
- Lab automation
- Hydrogels
- Keywords
- Burns
- Reconstructive surgery
- Skin grafts
- Cell therapy manufacturing
- Regenerative medicine
- Orphan drugs